Levobupivakain Kabi

Levobupivacaine Hydrochloride, the active ingredient in Levobupivakain Kabi, is a local anesthetic (amide) presented as a solution for epidural use. It provides regional loss of sensation for surgical, postoperative and obstetric procedures in adult patients. GNH USA supplies Levobupivakain Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levobupivacaine is a long‑acting amide local anesthetic used in regional anesthesia and analgesia. - Epidural anesthesia: produces reliable sensory block for surgical procedures requiring regional anesthesia. - Postoperative analgesia: extends pain relief after surgery, reducing the need for systemic opioids. - Obstetric analgesia: offers effective labor pain control while preserving maternal motor function.

Levobupivacaine may cause a range of adverse reactions, most of which are dose‑dependent and related to its local‑anaesthetic properties.

Common Side Effects: - Hypotension: transient drop in blood pressure after epidural administration. - Bradycardia: slowed heart rate, especially in patients with high vagal tone. - Nausea or vomiting: gastrointestinal upset following regional block. - Dizziness or light‑headedness: related to sympathetic blockade. - Metallic taste: transient sensation after systemic absorption.

Serious or Rare Side Effects: - Cardiac arrhythmia: potentially life‑threatening rhythm disturbances. - Central nervous system toxicity: seizures or altered mental status. - Respiratory depression: reduced ventilatory drive in high systemic levels. - Prolonged motor block: extended loss of muscle function beyond intended duration. - Allergic reaction: rash, urticaria or anaphylaxis in sensitised individuals.

Levobupivacaine should be administered by qualified clinicians with appropriate monitoring. - Dose adjustment: consider patient age, weight and hepatic function when selecting dose. - Cardiovascular monitoring: observe for hypotension, bradycardia and arrhythmias during and after injection. - Avoid intravascular injection: aspirate before administration and use incremental dosing. - Caution in hepatic impairment: reduced metabolism may increase systemic exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levobupivacaine may interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiotoxicity. - Beta‑blockers: may exacerbate bradycardia and hypotension. - Concurrent use of other local anesthetics: additive neuro‑ and cardiotoxic effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations. - Magnesium sulfate: potentiates neuromuscular blockade. - General anesthetics (e.g., propofol): can enhance central nervous system depression.